HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors

Creative Commons License

Files in This Item:
22175-314266-4-PB.pdf5.01 MBPDFView/Open
22175-314275-1-SP.pdfSupplementary Materials287.14 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/68612

Title: Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors
Authors: Hontani, Koji Browse this author
Tsuchikawa, Takahiro Browse this author →KAKEN DB
Hiwasa, Takaki Browse this author
Nakamura, Toru Browse this author →KAKEN DB
Ueno, Takashi Browse this author
Kushibiki, Toshihiro Browse this author
Takahashi, Mizuna Browse this author
Inoko, Kazuho Browse this author
Takano, Hironobu Browse this author
Takeuchi, Satoshi Browse this author
Dosaka-Akita, Hirotoshi Browse this author →KAKEN DB
Kuwatani, Masaki Browse this author →KAKEN DB
Sakamoto, Naoya Browse this author →KAKEN DB
Hatanaka, Yutaka Browse this author →KAKEN DB
Mitsuhashi, Tomoko Browse this author →KAKEN DB
Shimada, Hideaki Browse this author
Shichinohe, Toshiaki Browse this author →KAKEN DB
Hirano, Satoshi Browse this author →KAKEN DB
Keywords: pancreatic neuroendocrine tumors
SEREX
biomarker
prognostic factor
EID3
Issue Date: 5-Dec-2017
Publisher: Impact Journals
Journal Title: Oncotarget
Volume: 8
Issue: 63
Start Page: 106206
End Page: 106221
Publisher DOI: 10.18632/oncotarget.22175
Abstract: Pancreatic neuroendocrine tumors (pNETs) are relatively rare heterogenous tumors, comprising only 1-2% of all pancreatic neoplasms. The majority of pNETs are non-functional tumors (NF-pNETs) that do not produce hormones, and as such, do not cause any hormone-related symptoms. As a result, these tumors are often diagnosed at an advanced stage because patients do not present with specific symptoms. Although tumor markers are used to help diagnosis and predict some types of cancers, chromogranin A, a widely used tumor marker of pNETs, has significant limitations. To identify novel NF-pNET-associated antigens, we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX) and identified five tumor antigens (phosphatase and tensin homolog, EP300-interacting inhibitor of differentiation 3 [EID3], EH domain-containing protein 1, galactoside-binding soluble 9, and BRCA1-associated protein). Further analysis using the AlphaLISA (R) immunoassay to compare serum antibody levels revealed that antibody levels against the EID3 antigen was significantly higher in the patient group than in the healthy donor group (n = 25, both groups). In addition, higher serum anti-EID3 antibody levels in NF-pNET patients correlated with shorter disease-free survival. The AUC calculated by ROC analysis was 0.784 with moderate diagnostic accuracy. In conclusion, serum anti-EID3 antibody levels may be useful as a tumor marker for prediction of tumor recurrence in NF-pNETs.
Rights: http://creativecommons.org/licenses/by/3.0/
Type: article
URI: http://hdl.handle.net/2115/68612
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 土川 貴裕

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University